This text provides critical reviews of important topics in medicinal chemistry together with an emphasis on emerging topics in the biological sciences, which are expected to provide the basis for future therapies.

Annual Reports in Medicinal Chemistry provides timely and critical reviews of important topics in medicinal chemistry together with an emphasis on emerging topics in the biological sciences, which are expectedto provide the basis for entirely new future therapies.

Part 1 Central nervous system diseases, D.W. Robertson: recent advances in migraine therapy, T. Branchek and J.E. Audia
Alzheimer's disease - recent advances on the amyloid hypothesis, V. John et al
obesity - leptin-neuropeptide Y interactions in the control of body weight, D.R. Gehlert and M. Heiman
melatonin receptor ligands and their potential clinical applications, C.D. Mahle et al
corticotrophin-releasing hormone (CRH) receptors and the discovery of selective non-peptide CRH1 antagonists, P.J. Gilligan et al
recent advances
in neurokinin receptor antagonists, S.G. Mills. Part 2 Cardiovascular and pulmonary diseases, A.M. Doherty: endothelin inhibitors, X.-M. Cheng et al
antithrombotics/serine proteases, W.C. Ripka and G.P. Vlasuk
leukotriene modulators as therapeutic agents in asthma and other inflammatory diseases,
R.L. Bell et al
emerging opportunities in the treatment of
atherosclerosis, C.M. Hayward and M.J. Bamberger. Part 3 Cancer and infectious diseases, J.J. Plattner: new approaches and agents to overcome bacterial resistance, J.M. Domagala and J.P. Sanchez
bacterial genomics and the search for novel
antibiotics, L. Katz et al
resistance to antiretroviral drug therapy, A. Molla and W.E. Kohlbrenner
non-HIV antiviral
agents, S.H. Krawczyk and N. Bischofberger
recent advances
in antifungal agents, P.A. Lartey and C.M. Moehle
angiogenesis inhibitors, D. Powell et al
chemical inhibitors of cyclin-dependent kinases, K.G. Coleman et al. Part 4 Immunology, endocrinology and metabolic diseases, W.K. Hagmann: T lymphocyte potassium channel blockers, J.C. Kath et al
male contraception, D.W. Combs
new dermatological agents for the treatment of psoriasis, S. Nagpal and R.A.S. Chandraratna
selective cyclooxygenase-2 inhibitors, P. Prasit and D. Riendeau
growth hormone secretagogues, R.P. Nargund and L.H.T. Van
der Ploeg. Part 5 Topics in biology, W.W. Wong: novel gene switches for the regulation of gene expression
agents that block TNF-I synthesis or activity, R.A. Black et al
nuclear
orphan receptors - scientific progress and therapeutic opportunities, D.W. Robertson et al. Part 6 Topics in drug design and discovery, G.L. Trainor: discovery and identification of lead compounds from combinational mixtures, B.A. Beutal
electrospray mass spectrometric characterization of adducts between therapeutic agents and proteins, C. Fenselau
nonpeptide agonists for peptide receptors - lessons from ligands, E.E. Sugg
natural products research and pharmaceuticals in the 1990s, S.K. Wrigley and M.I. Chicarelli-Robinson
inhibition of cytochrome P-450 and implications in drug development, J.H. Lin and A.Y.H. Lu. Part 7 Trends and perspectives, J.A. Bristol: to market, to market - 1996, P. Galatsis.